- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Introduction and Current Landscape of HER2 in NSCLC
Panelists discuss how HER2-directed therapies in non–small cell lung cancer (NSCLC) are evolving, with experts examining the distinction between HER2 mutation and expression, evaluating the efficacy and safety of current treatments like trastuzumab deruxtecan and ado-trastuzumab emtansine, and considering their potential to reshape treatment approaches as recommended in NCCN guidelines.
EP: 1.Introduction and Current Landscape of HER2 in NSCLC
EP: 2.Safety and Efficacy of HER2-Directed ADCs for NSCLC
EP: 3.Treatment Considerations for Patients With HER2+ NSCLC
EP: 4.Latest Advances and Therapies for HER2+ NSCLC
EP: 5.Unmet Needs and Clinical Considerations for HER2+ NSCLC
EP: 6.Integrating HER2-Directed Therapies Into Standard Care for NSCLC
EP: 7.HER2- Mutation Testing Considerations and Timing
EP: 8.Factors Impacting Use of HER2 Therapies for NSCLC
EP: 9.Incorporating Real-World Evidence for HER2+ NSCLC
EP: 10.Key Takeaways on the Future of HER2 in NSCLC
EP: 11.Real-World Outcomes in HER2-Positive NSCLC
EP: 12.Managing Treatment Challenges in HER2-Directed Therapies
EP: 13.Emerging Horizons in HER2-Directed NSCLC Treatments
EP: 14.Patient Selection and Personalized Treatment Strategies
EP: 15.Navigating Healthcare Access and Decision-Making
Video content above is prompted by the following:
- Evaluate the efficacy and safety profiles of current and emerging HER2-directed therapies in NSCLC, and their potential impact on treatment paradigms.
- (Bazhenova) Describe the difference between HER2 mutation and HER2 expression.
- (Kim) Provide an overview of the current HER2-directed therapies (fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine) available and how they’re recommended in the NCCN guidelines.
High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer
January 16th 2025High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.
Read More
Real-World Evidence Confirms the Benefits of JAK Inhibitors in Patients With Rheumatoid Arthritis
January 16th 2025This systematic review of real-world observational studies demonstrated the effectiveness of Janus kinase (JAK) inhibitors in improving treatment adherence, persistence, clinical outcomes, and patient-reported outcomes among US patients with rheumatoid arthritis.
Read More
